Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You and Your Team.

Learn More →

Assessment of Clinical Activity of PD-1 Checkpoint Inhibitor Combination Therapies Reported in Clinical Trials.

Assessment of Clinical Activity of PD-1 Checkpoint Inhibitor Combination Therapies Reported in... Because cancer drugs given in combination have the potential for increased tumor-cell killing, finding the best combination partners for programmed cell death 1 (PD-1) checkpoint inhibitors could improve clinical outcomes for patients with cancer. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA network open Pubmed

Assessment of Clinical Activity of PD-1 Checkpoint Inhibitor Combination Therapies Reported in Clinical Trials.

Assessment of Clinical Activity of PD-1 Checkpoint Inhibitor Combination Therapies Reported in Clinical Trials.


Abstract

Because cancer drugs given in combination have the potential for increased tumor-cell killing, finding the best combination partners for programmed cell death 1 (PD-1) checkpoint inhibitors could improve clinical outcomes for patients with cancer.

Loading next page...
 
/lp/pubmed/assessment-of-clinical-activity-of-pd-1-checkpoint-inhibitor-ACZxOf7crA
ISSN
2574-3805
eISSN
2574-3805
DOI
10.1001/jamanetworkopen.2019.20833
pmid
32049290

Abstract

Because cancer drugs given in combination have the potential for increased tumor-cell killing, finding the best combination partners for programmed cell death 1 (PD-1) checkpoint inhibitors could improve clinical outcomes for patients with cancer.

Journal

JAMA network openPubmed

Published: Aug 24, 2020

References